Medicines labeled for the same conditions
Alternatives to glecaprevir and pibrentasvir
6 other medicines are given the same way (oral) and in the same FDA class as glecaprevir and pibrentasvir or labeled mainly for the same use (hepatitis c); 4 are in its class, hepatitis c virus ns3/4a protease inhibitors: ledipasvir and sofosbuvir, sofosbuvir and velpatasvir, elbasvir and grazoprevir and sofosbuvir and velpatasvir and voxilaprevir; the others include 1 nucleoside analog antiviral and 1 hepatitis c virus nucleotide analog ns5b polymerase inhibitor (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $278.03 per unit (Sofosbuvir-velpatasvir 400-100) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as glecaprevir and pibrentasvir?
Hepatitis C lists all 8 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Glecaprevir and pibrentasvirhepatitis c virus ns3/4a protease inhibitor | this medicine | none listed | $152.98 per tablet 100-40 mg tablet | Yes | No current entry |
| Ledipasvir and sofosbuvirhepatitis c virus nucleotide analog ns5b polymerase inhibitor · same class | Hepatitis C | none listed | n/a | Yes | No current entry |
| Sofosbuvir and velpatasvirhepatitis c virus nucleotide analog ns5b polymerase inhibitor · same class | Hepatitis C | none listed | $278.03 per unit 400-100 | Yes | No current entry |
| Elbasvir and grazoprevirhepatitis c virus ns3/4a protease inhibitor · same class | Hepatitis C | none listed | n/a | Yes | A presentation being discontinued |
| Sofosbuvir and velpatasvir and voxilaprevirhepatitis c virus ns3/4a protease inhibitor · same class | Hepatitis C | none listed | n/a | Yes | No current entry |
| Ribavirinnucleoside analog antiviral | Hepatitis C | 1 labeler | $0.451 per tablet 200 mg tablet | Yes | No current entry |
| Sofosbuvirhepatitis c virus nucleotide analog ns5b polymerase inhibitor | Hepatitis C | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Glecaprevir and pibrentasvir: the full record
- label, generics, price, shortages, recalls